$19.71
-0.24 (-1.20%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AVTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 2 with posted results
Held by 10 tracked-famous managers (Point72 Asset Management, L.P., Balyasny Asset Management L.P., Squarepoint Ops LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, +5 more) · FINRA short interest 14.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis SuppurativaNCT06603077Proportion of patients achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo | Hidradenitis Suppurativa | 253 | 2026-02-23actual | 2026-04-21 |
| A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.NCT05288504results2024-09-05The Ability of AVTX-002 to Improve Asthma Control in Subjects With Poorly Controlled Non-eosinophilic Asthma (NEA) Based on the Percentage of Patients Who Experience Asthma Related Events.Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: AVTX-002, Placebo | Non-Eosinophilic Asthma | 91 | 2023-05-11actual | 2024-09-05 |
| A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic MalformationsNCT04994002Safety and Tolerability of CERC-006 in Adults (Aged 18-31 Years) with Active, Moderate to Severe Complex Lymphatic MalformationsNon-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: CERC-006 | Lymphatic Malformation | 0 | Jun 2022 | 2022-03-22 |
| Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple MyelomaNCT04671251Recommended Phase 2 DoseOpen-label · Treatment | Phase 1 | Completed | Drug: AEVI-007 | Multiple Myeloma | 13 | 2022-03-30actual | 2024-02-29 |
| Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative ColitisNCT03169894results2024-02-26Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Strategic reasons | Drug: MDGN-002 | Crohn Disease, Ulcerative Colitis | 8 | 2021-09-14actual | 2024-02-26 |
| A Study of Intermittent Doses of CERC-301 in MDDNCT02459236Change in Bech-6 from baselineRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: CERC-301, Placebo | Major Depressive Disorder | 115 | Sep 2016actual | 2017-09-28 |
| A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant TreatmentNCT01941043HDRS-17 after 7 days of dosing with study drugRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: CERC-301 · Other: Placebo | Major Depressive Disorder | 1,357 | Sep 2014actual | 2017-12-21 |
| An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory CoughNCT01703923Cough Count/FrequencyRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: FP01, placebo | Chronic Refractory Cough | 83 | Sep 2013actual | 2014-11-05 |
| Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract InfectionNCT01597349Change in cough count, active vs placebo treatment periodRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: FP01 | Acute Cough | 208 | Sep 2012actual | 2014-02-28 |
| A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy VolunteersNCT01579526Plasma pharmacokinetic profiles of the active pharmaceutical ingredientRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: FP01 | Healthy | 40 | Apr 2012actual | 2012-05-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19